AAPL321.66-4.23 (-1.30%) ▼|ABBV256.92+3.62 (+1.43%) ▲|ABT100.75+0.18 (+0.18%) ▲|ACN138.74-1.35 (-0.96%) ▼|ADBE212.17-6.19 (-2.83%) ▼|AMAT562.80+8.88 (+1.60%) ▲|AMD539.69-12.64 (-2.29%) ▼|AMGN371.50+5.45 (+1.49%) ▲|AMT164.65-1.41 (-0.85%) ▼|AMZN233.66-11.19 (-4.57%) ▼|AVGO392.47-4.34 (-1.09%) ▼|AXP340.84-7.90 (-2.27%) ▼|BA209.23+0.58 (+0.28%) ▲|BAC61.28-0.34 (-0.55%) ▼|BKNG172.83-5.03 (-2.83%) ▼|BLK1,037.16-19.47 (-1.84%) ▼|BMY61.51+0.75 (+1.23%) ▲|BNY160.11-0.28 (-0.17%) ▼|BRK-B490.85+1.46 (+0.30%) ▲|C131.88-0.37 (-0.28%) ▼|CAT894.54+5.23 (+0.59%) ▲|CL90.08-1.55 (-1.69%) ▼|CMCSA21.92-1.60 (-6.80%) ▼|COF199.96-1.40 (-0.70%) ▼|COP120.20+1.41 (+1.19%) ▲|COST926.06-1.25 (-0.13%) ▼|CRM156.93-6.07 (-3.72%) ▼|CSCO112.76+0.55 (+0.49%) ▲|CVS106.89-0.53 (-0.49%) ▼|CVX194.42+1.44 (+0.75%) ▲|DE610.02+2.69 (+0.44%) ▲|DHR192.50+13.36 (+7.46%) ▲|DIS92.83-3.04 (-3.17%) ▼|DUK129.26+1.31 (+1.02%) ▲|EMR144.90+5.27 (+3.77%) ▲|FDX315.62-5.40 (-1.68%) ▼|GD381.79+8.63 (+2.31%) ▲|GE349.00+7.81 (+2.29%) ▲|GEV1,031.19+46.16 (+4.69%) ▲|GILD130.86+0.52 (+0.40%) ▲|GM80.67-1.46 (-1.78%) ▼|GOOG318.34-23.57 (-6.89%) ▼|GOOGL317.69-24.40 (-7.13%) ▼|GS1,074.72-23.48 (-2.14%) ▼|HD324.71-6.74 (-2.03%) ▼|HON246.27+13.28 (+5.70%) ▲|IBM206.65+0.88 (+0.43%) ▲|INTC100.23-2.39 (-2.33%) ▼|INTU281.53-2.94 (-1.03%) ▼|ISRG332.02-8.67 (-2.54%) ▼|JNJ259.27+3.64 (+1.42%) ▲|JPM349.90+1.69 (+0.49%) ▲|KO81.17-1.03 (-1.25%) ▼|LIN506.32-2.35 (-0.46%) ▼|LLY1,185.87+22.86 (+1.97%) ▲|LMT568.59+54.23 (+10.54%) ▲|LOW201.92-2.43 (-1.19%) ▼|LRCX319.78+0.49 (+0.15%) ▲|MA530.29-1.69 (-0.32%) ▼|MCD262.80-0.77 (-0.29%) ▼|MDLZ60.05-0.81 (-1.33%) ▼|MDT82.01+0.12 (+0.15%) ▲|META606.10-21.07 (-3.36%) ▼|MMM169.59-1.17 (-0.69%) ▼|MO72.08-0.09 (-0.12%) ▼|MRK130.48+3.01 (+2.36%) ▲|MS215.18-3.32 (-1.52%) ▼|MSFT381.58-8.76 (-2.24%) ▼|MU990.21+30.73 (+3.20%) ▲|NEE89.79+0.38 (+0.43%) ▲|NFLX68.89+0.36 (+0.53%) ▲|NKE40.99-1.22 (-2.89%) ▼|NOW91.94-3.52 (-3.69%) ▼|NVDA208.76-3.30 (-1.56%) ▼|ORCL120.04-5.80 (-4.61%) ▼|PEP134.95-0.70 (-0.52%) ▼|PFE25.01+0.19 (+0.77%) ▲|PG146.97-2.16 (-1.45%) ▼|PLTR123.37-1.20 (-0.96%) ▼|PM191.12-3.18 (-1.64%) ▼|QCOM171.11-4.52 (-2.57%) ▼|RTX209.16+14.28 (+7.33%) ▲|SBUX103.21-0.77 (-0.74%) ▼|SCHW101.61+0.81 (+0.80%) ▲|SO96.60+0.80 (+0.84%) ▲|SPG225.20-1.02 (-0.45%) ▼|T22.96-0.08 (-0.35%) ▼|TMO572.32+45.86 (+8.71%) ▲|TMUS170.42-20.52 (-10.75%) ▼|TSLA319.69-54.32 (-14.52%) ▼|TXN284.99-9.20 (-3.13%) ▼|UBER68.91-1.42 (-2.02%) ▼|UNH423.56-7.75 (-1.80%) ▼|UNP304.33+11.77 (+4.02%) ▲|UPS114.10-1.74 (-1.50%) ▼|USB63.33-1.14 (-1.77%) ▼|V351.60-1.82 (-0.52%) ▼|VZ43.82-0.47 (-1.06%) ▼|WFC86.19-0.23 (-0.27%) ▼|WMT108.40-0.93 (-0.85%) ▼|XOM156.89+2.44 (+1.58%) ▲|AAPL321.66-4.23 (-1.30%) ▼|ABBV256.92+3.62 (+1.43%) ▲|ABT100.75+0.18 (+0.18%) ▲|ACN138.74-1.35 (-0.96%) ▼|ADBE212.17-6.19 (-2.83%) ▼|AMAT562.80+8.88 (+1.60%) ▲|AMD539.69-12.64 (-2.29%) ▼|AMGN371.50+5.45 (+1.49%) ▲|AMT164.65-1.41 (-0.85%) ▼|AMZN233.66-11.19 (-4.57%) ▼|AVGO392.47-4.34 (-1.09%) ▼|AXP340.84-7.90 (-2.27%) ▼|BA209.23+0.58 (+0.28%) ▲|BAC61.28-0.34 (-0.55%) ▼|BKNG172.83-5.03 (-2.83%) ▼|BLK1,037.16-19.47 (-1.84%) ▼|BMY61.51+0.75 (+1.23%) ▲|BNY160.11-0.28 (-0.17%) ▼|BRK-B490.85+1.46 (+0.30%) ▲|C131.88-0.37 (-0.28%) ▼|CAT894.54+5.23 (+0.59%) ▲|CL90.08-1.55 (-1.69%) ▼|CMCSA21.92-1.60 (-6.80%) ▼|COF199.96-1.40 (-0.70%) ▼|COP120.20+1.41 (+1.19%) ▲|COST926.06-1.25 (-0.13%) ▼|CRM156.93-6.07 (-3.72%) ▼|CSCO112.76+0.55 (+0.49%) ▲|CVS106.89-0.53 (-0.49%) ▼|CVX194.42+1.44 (+0.75%) ▲|DE610.02+2.69 (+0.44%) ▲|DHR192.50+13.36 (+7.46%) ▲|DIS92.83-3.04 (-3.17%) ▼|DUK129.26+1.31 (+1.02%) ▲|EMR144.90+5.27 (+3.77%) ▲|FDX315.62-5.40 (-1.68%) ▼|GD381.79+8.63 (+2.31%) ▲|GE349.00+7.81 (+2.29%) ▲|GEV1,031.19+46.16 (+4.69%) ▲|GILD130.86+0.52 (+0.40%) ▲|GM80.67-1.46 (-1.78%) ▼|GOOG318.34-23.57 (-6.89%) ▼|GOOGL317.69-24.40 (-7.13%) ▼|GS1,074.72-23.48 (-2.14%) ▼|HD324.71-6.74 (-2.03%) ▼|HON246.27+13.28 (+5.70%) ▲|IBM206.65+0.88 (+0.43%) ▲|INTC100.23-2.39 (-2.33%) ▼|INTU281.53-2.94 (-1.03%) ▼|ISRG332.02-8.67 (-2.54%) ▼|JNJ259.27+3.64 (+1.42%) ▲|JPM349.90+1.69 (+0.49%) ▲|KO81.17-1.03 (-1.25%) ▼|LIN506.32-2.35 (-0.46%) ▼|LLY1,185.87+22.86 (+1.97%) ▲|LMT568.59+54.23 (+10.54%) ▲|LOW201.92-2.43 (-1.19%) ▼|LRCX319.78+0.49 (+0.15%) ▲|MA530.29-1.69 (-0.32%) ▼|MCD262.80-0.77 (-0.29%) ▼|MDLZ60.05-0.81 (-1.33%) ▼|MDT82.01+0.12 (+0.15%) ▲|META606.10-21.07 (-3.36%) ▼|MMM169.59-1.17 (-0.69%) ▼|MO72.08-0.09 (-0.12%) ▼|MRK130.48+3.01 (+2.36%) ▲|MS215.18-3.32 (-1.52%) ▼|MSFT381.58-8.76 (-2.24%) ▼|MU990.21+30.73 (+3.20%) ▲|NEE89.79+0.38 (+0.43%) ▲|NFLX68.89+0.36 (+0.53%) ▲|NKE40.99-1.22 (-2.89%) ▼|NOW91.94-3.52 (-3.69%) ▼|NVDA208.76-3.30 (-1.56%) ▼|ORCL120.04-5.80 (-4.61%) ▼|PEP134.95-0.70 (-0.52%) ▼|PFE25.01+0.19 (+0.77%) ▲|PG146.97-2.16 (-1.45%) ▼|PLTR123.37-1.20 (-0.96%) ▼|PM191.12-3.18 (-1.64%) ▼|QCOM171.11-4.52 (-2.57%) ▼|RTX209.16+14.28 (+7.33%) ▲|SBUX103.21-0.77 (-0.74%) ▼|SCHW101.61+0.81 (+0.80%) ▲|SO96.60+0.80 (+0.84%) ▲|SPG225.20-1.02 (-0.45%) ▼|T22.96-0.08 (-0.35%) ▼|TMO572.32+45.86 (+8.71%) ▲|TMUS170.42-20.52 (-10.75%) ▼|TSLA319.69-54.32 (-14.52%) ▼|TXN284.99-9.20 (-3.13%) ▼|UBER68.91-1.42 (-2.02%) ▼|UNH423.56-7.75 (-1.80%) ▼|UNP304.33+11.77 (+4.02%) ▲|UPS114.10-1.74 (-1.50%) ▼|USB63.33-1.14 (-1.77%) ▼|V351.60-1.82 (-0.52%) ▼|VZ43.82-0.47 (-1.06%) ▼|WFC86.19-0.23 (-0.27%) ▼|WMT108.40-0.93 (-0.85%) ▼|XOM156.89+2.44 (+1.58%) ▲|
22.1 C
New York
Friday, July 24, 2026

Tag: healthcare company

newssourceFORcompanyinformationcontent1releasesmarket

New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway

Drugmakers run the largest direct-to-consumer advertising category in the United States. New 5W research finds AI citation share does not follow the ad budget...

$GRAL Fraud Notice: GRAIL, Inc. Accused of Securities Fraud over Trial Results in Filed Class Action Lawsuit – Investors Notified to Contact BFA Law

GRAIL, Inc. Accused of Securities Fraud over Trial Results in Filed Class Action Lawsuit – Investors Notified to Contact BFA Law

GRAL INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The case alleges that Grail’s top executives made false and/or misleading statements to investors.

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Novo Nordisk's Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity for adults

Subtle Medical Receives FDA Clearance for SubtleHD™(CT), Expanding AI-Powered Image Enhancement into CT Imaging

New software enhances CT image quality across scanner generations, supporting radiologists with improved image clarity and consistencyMENLO PARK, Calif., June 10, 2026 /PRNewswire/ --...

Dong Bang Co Ltd Strengthens Global Competitiveness with Advanced Veterinary Pharmaceuticals

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dong Bang Co Ltd is strengthening its position in the global veterinary pharmaceutical market with high-value...

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship will help expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C.,...

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk is launching Wegovy® pill in the UAE, the first country outside the US, to make the Wegovy® pill available to people living with obesity

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHealthcare company

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers